Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (NASDAQ:REGN) and Align Tech (NASDAQ:ALGN).
Regeneron (REGN)
Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Regeneron on July 13 and set a price target of $396. The company’s shares closed on Friday at $367.64.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.7% and a 65.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Sarepta Therapeutics, and Editas Medicine Inc.
Regeneron has an analyst consensus of Moderate Buy, with a price target consensus of $373.50, representing a 1.6% upside. In a report issued on July 2, SunTrust Robinson also maintained a Hold rating on the stock with a $344 price target.
.
See today’s analyst top recommended stocks >>
Align Tech (ALGN)
In a report issued on July 13, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Align Tech, with a price target of $375. The company’s shares closed on Friday at $363.45, close to its 52-week high of $371.55.
According to TipRanks.com, Block is a 5-star analyst with an average return of 23.2% and a 75.6% success rate. Block covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA Inc, Idexx Laboratories, and Hologic.
Currently, the analyst consensus on Align Tech is a Strong Buy with an average price target of $344.60.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
